Posted on May 27th, 2021
Courtesy Adaderana
Vaccines from China’s Sinopharm successfully contained Covid-19, according to a study published in a prestigious U.S. medical journal, the first time detailed findings from a late-stage trial of a Chinese shot have appeared in the scientific literature.
The two inactivated vaccines developed by Sinopharm’s vaccine-making unit China National Biotec Group Co. prevented symptomatic infections by 72.8% and 78.1%, largely in-line with what the state-owned drugmaker previously announced. The findings were reported in the May 26 Journal of the American Medical Association (JAMA).
Chinese shots, including those from Sinopharm and Sinovac Biotech Ltd., another Beijing-based vaccine maker, have formed the backbone of the vaccine rollout in developing countries ranging from Hungary and Serbia to Seychelles and Peru. The immunizations have come under scrutiny and their manufacturers have been criticized for not sharing
China’s Sinopharm Publishes Long-Awaited Vaccine Trial Findings
The two inactivated vaccines developed by Sinopharm’s vaccine-making unit prevented symptomatic infections by 72.8% and 78.1%, largely in-line with what the state-owned drugmaker previously announced. Photo: VCG
(Bloomberg) Vaccines from China’s Sinopharm successfully contained Covid-19, according to a study published in a prestigious U.S. medical journal, the first time detailed findings from a late-stage trial of a Chinese shot have appeared in the scientific literature.
The two inactivated vaccines developed by Sinopharm’s vaccine-making unit China National Biotec Group Co. Ltd. prevented symptomatic infections by 72.8% and 78.1%, largely in-line with what the state-owned drugmaker previously announced. The findings were reported in the May 26 Journal of the American Medical Association (JAMA).
Covid Origin Hunt Ordered by U S ; EU Rips Astra: Virus Update bloombergquint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bloombergquint.com Daily Mail and Mail on Sunday newspapers.
(0)
Results of Split-Face Study to Determine the Efficacy and Safety of 2.5% Agarose Gel Filler for the Correction of Nasolabial Folds Published in Peer Reviewed Journal
BROOKLINE, Mass., May 25, 2021 /PRNewswire/ Advanced Aesthetic Technologies, Inc. (AAT), a leader in aesthetic gel implant technology, is proud to announce that Algeness VL (2.5% Agarose Gel) demonstrated equivalent efficacy, safety, and usability compared to those of NASHA-L based on a split-face study published in the Journal of Cosmetic Dermatology. Agarose gel filler is a naturally occurring polymer gel with a three-dimensional structure similar to the extracellular matrix, which achieves its duration without the need for crosslinking. Our objective with this study of 66 patients was to determine the efficacy and safety of 2.5% agarose gel filler for the correction of nasolabial folds as compared with NASHA-L. Our assessments included assessment of the nasolabial fold (NLF), Wrinkle Severity Rating Scale
Comparison of Advanced Aesthetic Technologies, Inc s 2 5% Agarose Gel with Hyaluronic Acid Filler for the Correction of Moderate to Severe Nasolabial Folds Reveals Equivalent Results adnkronos.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adnkronos.com Daily Mail and Mail on Sunday newspapers.